Essential Partners’s Climb Bio CLYM Stock Holding History

Essential Partners’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-63	Closed	-$78	–	2810
2025 Q2	$78	Buy	+63	New	+$78	﹤0.01%	2099

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Essential Partners's CLYM Position: Q3 2025 in Review

Essential Partners sold out of Climb Bio (CLYM) in Q3 2025, closing a stake of 63 shares — an estimated $78 sold.

Essential Partners first reported a position in CLYM in Q2 2025 and held it in 1 quarter. The position peaked at $78 in Q2 2025. 68 funds tracked by Wall St. Rank hold CLYM as of Q3 2025.

Essential Partners reported no remaining Climb Bio position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 63 Climb Bio shares in Q3 2025, an estimated $78.
Essential Partners first reported a position in Climb Bio in Q2 2025 and held it in 1 quarter.
Essential Partners's Climb Bio position peaked at $78 in Q2 2025.
68 funds tracked by Wall St. Rank held Climb Bio as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.